Cannakeys

Unlocking the Science of Cannabis

CK Home / Detail

PRIMARY STUDY

A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

Key Findings:  This case study reviews a patient who developed posterior reversible encephalopathy syndrome (PRES) after consuming the synthetic cannabinoid K2. K2 is not detected in routine drug screening, so clinicians must maintain awareness of this compound in patients with clinical suspicion of synthetic cannabis use.

Type of Study:  Meta-analysis

Study Sample Size:  1

Study Result:  Negative

Research Location(s):  Pakistan, United States

Year of Pub:  2022


Cannabinoids Studied:  Tetrahydrocannabinol (THC), Synthetic Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  CB1, CB2, CB1 agonist

Route of Administration:  Oral (Ingestion)




Citation:  Ghazanfar H, et al. A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES). Am J Case Rep. 2022; 23:e936209. doi: 10.12659/AJCR.936209

Authors:  Ghazanfar H, Muthumanickam A, Qureshi Z, Altaf F, Zeana C, Chilimuri S